We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax to Supply Coronavirus Vaccine to Canadian Government
Read MoreHide Full Article
Novavax, Inc. (NVAX - Free Report) announced that it has reached an agreement in principle with the Canadian government, which is looking to purchase up to 76 million doses of its COVID-19 vaccine candidate NVX-CoV2373. The company is looking to supply the same as early as the second quarter of 2021.
NVX-CoV2373 is a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology and includes its proprietary Matrix M adjuvant. The vaccine candidate is currently being evaluated in several phase II studies.
Shares of Novavax have skyrocketed 2672.3% so far this year compared with the industry’s increase of 1.2%.
Last month, Novavax signed a Heads of Terms (Term Sheet) with the government of the United Kingdom to supply 60 million doses of NVX-CoV2373. We note that the majority of governments are trying to secure vaccine doses for their people as soon as they are approved. Hence, we expect more such supply deals to be sealed across the globe.
Also, in August 2020, Novavax enrolled the first volunteer in the phase II portion of its ongoing phase I/II study, which is evaluating the immunogenicity and safety of NVX-CoV2373. The study will recruit up to 1,500 healthy volunteers in the United States and Australia with approximately 50% patients aged between 60 years and 84 years of age. Novavax also initiated a phase IIb study to evaluate the efficacy of NVX-CoV2373 in South Africa during the month.
We remind investors that in August, Novavax released encouraging results from the first human trial of its COVID-19 vaccine candidate. The clinical study data showed that the vaccine was generally well-tolerated and elicited robust antibody responses, numerically superior to what was seen in human convalescent sera (antibodies derived from blood donated by people who recovered from the illness).
The company received $2-billion funding, roughly divided into the U.S. Department of Defense’s aid of $60 million, the CEPI’s $388-million donation and the U.S. government’s OWS grant of $1.6 billion for developing NVX-CoV2373.
Novavax is one of the dozen companies developing a vaccine for the deadly coronavirus disease. Several big companies, such as AstraZeneca (AZN - Free Report) /Oxford University, Moderna (MRNA - Free Report) and Pfizer (PFE - Free Report) along with its Germany-based partner BioNTech already initiated their phase III studies on the COVID-19 vaccine. In the current scenario, we expect this race against time to get an approval for a potential COVID-19 vaccine to intensify in the upcoming months.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Shutterstock
Novavax to Supply Coronavirus Vaccine to Canadian Government
Novavax, Inc. (NVAX - Free Report) announced that it has reached an agreement in principle with the Canadian government, which is looking to purchase up to 76 million doses of its COVID-19 vaccine candidate NVX-CoV2373. The company is looking to supply the same as early as the second quarter of 2021.
NVX-CoV2373 is a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology and includes its proprietary Matrix M adjuvant. The vaccine candidate is currently being evaluated in several phase II studies.
Shares of Novavax have skyrocketed 2672.3% so far this year compared with the industry’s increase of 1.2%.
Last month, Novavax signed a Heads of Terms (Term Sheet) with the government of the United Kingdom to supply 60 million doses of NVX-CoV2373. We note that the majority of governments are trying to secure vaccine doses for their people as soon as they are approved. Hence, we expect more such supply deals to be sealed across the globe.
Also, in August 2020, Novavax enrolled the first volunteer in the phase II portion of its ongoing phase I/II study, which is evaluating the immunogenicity and safety of NVX-CoV2373. The study will recruit up to 1,500 healthy volunteers in the United States and Australia with approximately 50% patients aged between 60 years and 84 years of age. Novavax also initiated a phase IIb study to evaluate the efficacy of NVX-CoV2373 in South Africa during the month.
We remind investors that in August, Novavax released encouraging results from the first human trial of its COVID-19 vaccine candidate. The clinical study data showed that the vaccine was generally well-tolerated and elicited robust antibody responses, numerically superior to what was seen in human convalescent sera (antibodies derived from blood donated by people who recovered from the illness).
The company received $2-billion funding, roughly divided into the U.S. Department of Defense’s aid of $60 million, the CEPI’s $388-million donation and the U.S. government’s OWS grant of $1.6 billion for developing NVX-CoV2373.
Novavax is one of the dozen companies developing a vaccine for the deadly coronavirus disease. Several big companies, such as AstraZeneca (AZN - Free Report) /Oxford University, Moderna (MRNA - Free Report) and Pfizer (PFE - Free Report) along with its Germany-based partner BioNTech already initiated their phase III studies on the COVID-19 vaccine. In the current scenario, we expect this race against time to get an approval for a potential COVID-19 vaccine to intensify in the upcoming months.
Zacks Rank
Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>